EFPIA Names Joe Jimenez as New President
EFPIA announced that Joe Jimenez, CEO of Novartis, has been appointed as its new president, following confirmation by the EFPIA Board on December 9. Jimenez will work alongside Dr. Stefan Oschmann, CEO Pharma of Merck KGaA, and Marc de Garidel, Chairman and CEO of Ipsen, who have been appointed as vice-presidents by the Board, also on December 9.
Jimenez previously served as EFPIA vice-president. He was already EFPIA’s president-elect at the time of former EFPIA president Chris Viehbacher’s resignation on October 29, 2014 and due to take over leadership of EFPIA in June 2015. The Board has agreed to extend Joe Jimenez’s appointment until June 2017; this is to be ratified during the EFPIA General Assembly in June 2015.
Source: EFPIA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
